SELLAS Life Sciences (SLS) Total Current Liabilities (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Total Current Liabilities data on file, last reported at $6.5 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $6.5 million, down 6.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.5 million (down 6.27% YoY), and the FY2025 annual result was $7.0 million, down 26.21% from the prior year.
• Total Current Liabilities retreated to $6.5 million in Q1 2026 per SLS's latest filing, from $7.0 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $15.5 million in Q4 2022 and troughed at $5.9 million in Q3 2025.
• A 5-year average of $10.8 million and a median of $11.7 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities soared 211.42% in 2022, then plunged 52.29% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $15.5 million in 2022, then fell by 11.47% to $13.7 million in 2023, then tumbled by 30.76% to $9.5 million in 2024, then declined by 26.21% to $7.0 million in 2025, then retreated by 7.99% to $6.5 million in 2026.
• Business Quant data shows SLS's Total Current Liabilities at $6.5 million in Q1 2026, $7.0 million in Q4 2025, and $5.9 million in Q3 2025.